Relmada Therapeutics recently reported past 12‑month interim Phase 2 data for NDV-01 in high-risk non-muscle invasive bladder cancer, showing strong complete response rates and a favorable safety ...
Incyte Provides Top-Line Results from Phase II Proof-of-Concept Trial of Ruxolitinib in Patients wit
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq: INCY) announced top-line results of the Phase II, randomized, double-blind, placebo-controlled RECAP trial of ruxolitinib, its oral JAK1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results